102 related articles for article (PubMed ID: 8823310)
1. Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.
van Zaanen HC; Koopmans RP; Aarden LA; Rensink HJ; Stouthard JM; Warnaar SO; Lokhorst HM; van Oers MH
J Clin Invest; 1996 Sep; 98(6):1441-8. PubMed ID: 8823310
[TBL] [Abstract][Full Text] [Related]
2. Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study.
van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; van der Lelie J; van Oers MH
Br J Haematol; 1998 Aug; 102(3):783-90. PubMed ID: 9722307
[TBL] [Abstract][Full Text] [Related]
3. Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.
Colnot DR; Quak JJ; Roos JC; van Lingen A; Wilhelm AJ; van Kamp GJ; Huijgens PC; Snow GB; van Dongen GA
J Nucl Med; 2000 Dec; 41(12):1999-2010. PubMed ID: 11138685
[TBL] [Abstract][Full Text] [Related]
4. Blocking interleukin-6 activity with chimeric anti-IL6 monoclonal antibodies in multiple myeloma: effects on soluble IL6 receptor and soluble gp130.
Van Zaanen HC; Lokhorst HM; Aarden LA; Rensink HJ; Warnaar SO; Van Oers MH
Leuk Lymphoma; 1998 Nov; 31(5-6):551-8. PubMed ID: 9922045
[TBL] [Abstract][Full Text] [Related]
5. Modulation of chronic excessive interleukin-6 production in multiple myeloma does not affect thyroid hormone concentrations.
van Zaanen HC; Romijn JA; Sauerwein HP; Lokhorst HM; Warnaar SO; Aarden LA; Endert E; van Oers MH
Metabolism; 1997 Nov; 46(11):1343-8. PubMed ID: 9361697
[TBL] [Abstract][Full Text] [Related]
6. [Tuberculosis in compromised hosts].
Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
Wong JY; Thomas GE; Yamauchi D; Williams LE; Odom-Maryon TL; Liu A; Esteban JM; Neumaier M; Dresse S; Wu AM; Primus FJ; Shively JE; Raubitschek AA
J Nucl Med; 1997 Dec; 38(12):1951-9. PubMed ID: 9430476
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
[TBL] [Abstract][Full Text] [Related]
9. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
Wang YD; Hu Y; Zhang L; Huang J; Sun CY
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
[TBL] [Abstract][Full Text] [Related]
10. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Palumbo A; Avonto I; Bruno B; Ambrosini MT; Bringhen S; Cavallo F; Falco P; Boccadoro M
Eur J Haematol; 2006 Apr; 76(4):273-7. PubMed ID: 16519697
[TBL] [Abstract][Full Text] [Related]
11. Decreased production of anti-mouse antibody after administration of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate to human.
Yata Y; Otsuji E; Okamoto K; Tsuruta H; Kobayashi S; Toma A; Yamagishi H
Hepatogastroenterology; 2003; 50(49):80-4. PubMed ID: 12629996
[TBL] [Abstract][Full Text] [Related]
12. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
13. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
14. Tumor-targeting properties of novel immunocytokines based on murine IL1β and IL6.
Hess C; Neri D
Protein Eng Des Sel; 2014 Jun; 27(6):207-13. PubMed ID: 24795343
[TBL] [Abstract][Full Text] [Related]
15. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
[TBL] [Abstract][Full Text] [Related]
16. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study.
Nishimoto N; Yoshizaki K; Maeda K; Kuritani T; Deguchi H; Sato B; Imai N; Suemura M; Kakehi T; Takagi N; Kishimoto T
J Rheumatol; 2003 Jul; 30(7):1426-35. PubMed ID: 12858437
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of limited blood sampling in a preceding 99mTc-labeled diagnostic study to predict the pharmacokinetics and myelotoxicity of 186Re-cMAb U36 radioimmunotherapy.
Colnot DR; Wilhelm AJ; Cloos J; Roos JC; de Bree R; Quak JJ; Snow GB; van Dongen GA
J Nucl Med; 2001 Sep; 42(9):1364-7. PubMed ID: 11535726
[TBL] [Abstract][Full Text] [Related]
18. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo.
Lu ZY; Brochier J; Wijdenes J; Brailly H; Bataille R; Klein B
Eur J Immunol; 1992 Nov; 22(11):2819-24. PubMed ID: 1425909
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone, paclitaxel, etoposide, cyclophosphamide (d-TEC) and G-CSF for stem cell mobilisation in multiple myeloma.
Bilgrami S; Bona RD; Edwards RL; Li Z; Naqvi B; Shaikh A; Furlong F; Fox J; Clive J; Tutschka PJ
Bone Marrow Transplant; 2001 Jul; 28(2):137-43. PubMed ID: 11509931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]